Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review
Nutrients · 2023
DOI: 10.3390/nu15040834 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Nutrients, 2023. Verfasst von Kok-Yong Chin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Tocotrienols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University of Malaysia, Universiti Kebangsaan Malaysia.
Abstract (Originalsprache)
The increasing burden of nonalcoholic fatty liver disease (NAFLD) requires innovative management strategies, but an effective pharmacological agent has yet to be found. Apart from weight loss and lifestyle adjustments, one isomer of the vitamin E family—alpha-tocopherol—is currently recommended for nondiabetic steatohepatitis patients. Another member of the vitamin E family, tocotrienol (T3), has anti-inflammatory and antioxidant properties that reach beyond those of alpha-tocopherol, making it a potential agent for use in NAFLD management. This systematic review aimed to provide an overview of the effects of T3 supplementation on NAFLD from both clinical and preclinical perspectives. A literature search was performed in October 2022 using PubMed, Scopus and Web of Science. Original research articles reporting NAFLD outcomes were included in this review. The search located 12 articles (8 animal studies and 4 human studies). The literature reports state that T3 isomers or natural mixtures (derived from palm or annatto) improved NAFLD outcomes (liver histology, ultrasound or liver profile). However, the improvement depended on the severity of NAFLD, study period and type of intervention (isomers/mixture of different compositions). Mechanistically, T3 improved lipid metabolism and prevented liver steatosis, and reduced mitochondrial and endoplasmic reticulum stress, inflammation and ultimately liver fibrosis. In summary, T3 could be a potential agent for use in managing NAFLD, pending more comprehensive preclinical and human studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
- Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
- American River Nutrition, Hadley, MA 01035, USA.
ORCID-Profile: Kok-Yong Chin, Sophia Ogechi Ekeuku
Förderung
- National University of Malaysia
- Universiti Kebangsaan Malaysia
Zitieren
APA
Chin, K. Y., Ekeuku, S. O., Chew, D. C. H., & Trias, A. (2023). Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review. Nutrients. https://doi.org/10.3390/nu15040834
Vancouver
Chin KY, Ekeuku SO, Chew DCH, Trias A. Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review. Nutrients. 2023. doi:10.3390/nu15040834
BibTeX
@article{Chin2023,
author = {Chin, Kok-Yong and Ekeuku, Sophia Ogechi and Chew, Deborah Chia Hsin and Trias, Anne},
title = {Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15040834}
}
EUVIMED